PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/pf.v9i4.390
Abstract
Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic therapy for the treatment of JIA in Russian children and adolescents. Materials and Methods. A Markov model was developed on the basis of the DE038 clinical trial, which compared ADA plus methotrexate (MTX) vs. placebo plus MTX for the treatment of JIA in children aged 4–17 years. Cost-effectiveness analyses were performed from the standpoint of the Russian health care system and society as a whole. Base case analyses followed 11-year-old patients with JIA for a period of 7 years (until the age of 18 years) or over an expected lifetime. Additional analyses followed patients aged 7 years at treatment initiation for a period of 11 years or over a simulated lifetime. The cost of treating severe JIA was assumed to be the same as reported in a published investigation. The cost of ADA therapy was based on the expected cost assuming inclusion in the List of Vital and Essential Medicinal Products. This took into account the Value Added Tax and a 10% trade mark-up. Treatment outcomes were measured in quality-adjusted life years (QALYs). Results and Discussion. Over a 7-year time horizon, the incremental cost-utility ratio (ICUR) for ADA vs. conventional nonbiologic therapy in the treatment of JIA in 11-year-old patients was 1,571,500 roubles/QALY when using a health care system perspective and 1,515,000 roubles/QALY when using a societal perspective. Over a simulated patient lifetime, the corresponding ICURs were 286,300 roubles/QALY and 275,300 roubles/QALY, respectively. Over an 11-year time horizon, the ICUR for ADA vs. conventional non-biologic therapy in the treatment of JIA in patients aged 7 years at the start of therapy was 852,400 roubles/QALY when using a health system perspective and 802,900 roubles/QALY when using a societal perspective. The corresponding ICURs were 229,700 roubles/QALY and 215,500 roubles/QALY, respectively, when modeling cost effectiveness over a simulated patient lifetime. In each set of analyses, the ICUR for ADA over conventional therapy declined precipitously when taking the long-term consequences of JIA into account. Conclusions. Relative to conventional non-biologic therapy, ADA is cost effective when used to treat JIA patients whose disease severity is comparable to that of participants in DE038. ICURs estimated in the base case lifetime analyses did not exceed the per-capita gross domestic product (GDP) for the Russian Federation — i. e., approximately 380,000 roubles in 2011— which is regarded as the upper threshold for highly cost-effective interventions. These findings support the use of ADA in clinical practice.
About the Authors
K. Simpson
Medical University of South Carolina, USA
United States
United States
N. Marlow
Medical University of South Carolina, USA
United States
United States
J. Shaw
Abbott, USA
United States
United States
А. V. Rudakova
Saint Petersburg Chemical and Pharmaceutical Academy
Russian Federation
Russian Federation
References
1. Feldman D., Bernatsky S., Houde M. The incidence of juvenile rheumatoid arthritis in Quebec: a population data-based study. Pediatr. Rheumatol. Online J. 2009; 7: 20.
2. Costa V., Ungar W. J., Hancock R. The use of biologic response modifiers in polyarticular-course juvenile ideopatic arthritis. Report No. 2010-01. January 11, 2010. http://pede.ccb.sickkids.ca/pde/task.jsp.
3. Yagudina R.I., Zinchuk I.Yu., Kulikov A.Yu. Farmako eko no micheskii analiz primeneniya genno-injenernyh biologicheskih preparatov pri yuvenil'nom revmatoidnom artrite. Farmakoekonomika 2011; 4 (1): 18–23.
4. Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenile
5. ideopatic arthritis and juvenile ankylosing spondylitis // Clin. Exp. Rheumatol. 2007; 25 (6):922–7.
6. Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life. Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.
7. Weiss J., Ilowite N. Juvenile idiopathic arthritis. Pediatrics Clinics of North America 2005; 52: 413–442.
8. Lovell D. J., Ruperto N., Goodman S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Eng. J. Med. 2008; 359: 810–20.
9. Life tables for WHO Member States. Russian Federation. 2009. (www.who.int)
10. Prilojeniya k General'nomu tarifnomu soglasheniyu po tarifam na medicinskuyu pomosch' (medicinskie uslugi) i usloviyam oplaty medicinskoi pomoschi, okazyvaemoi v ramkah deistvuyuschei Territorial'noi programmy obyazatel'nogo medicinskogo strahovaniya grajdan Rossiiskoi Federacii v Sankt-Peterburge na 2011 g. (www.spboms.ru)
11. Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: Health burden and cost. Eur. J. Health Econ. 2008; 8 (Suppl. 2): S49-S60.
12. Simpson K.N., Shaw J.W. Mapping the Childhood Health Assessment Questionnaire to the Health Utilities Index Mark 2 and
13. Mark 3 in children with juvenile idiopathic arthritis [abstract]. Quality of Life Research. In press 2012.
14. Andersson G.B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence // Clin Exp Rheumatol. 1999; 17: 367–74.
15. Bernatsky S., Duffy C., Malleson P., Feldman D.E., St. Pierre Y., Clarke A. Economic impact of juvenile idiopathic arthritis//Arthritis and Rheumatism. 2007; 15: 44–48.
16. Lam K., Young N., Marwaha j. et al. Revised version of the Childhood Health Assessment Questionnaire (CHAQ) are more sensitive and suffer less from a ceiling effect. Arthritis & Rheumatism. 2004; 51 (6); 881–889.
17. Packham J.C., Hall M.A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome // Rheumatology. 2002; 41: 1428–1435.
18. Torrance G.W., Feeny D.H., Furlong W.J., Barr R.D., Zhang Y., Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 // Medical Care 1996; 34 (7): 702–722.
19. Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: hHealth burden and cost // Eur. J. Health Econ. 2008; 8 (Suppl. 2): S49-S60.
20. Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenile ideopatic arthritis and juvenile ankylosing spondylitis // Clin. Exp. Rheumatol. 2007; 25 (6): 922–7.
21. Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life // Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.
Review
For citations:
Simpson K., Marlow N., Shaw J., Rudakova А.V. PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS. Pediatric pharmacology. 2012;9(4):48-59. (In Russ.) https://doi.org/10.15690/pf.v9i4.390
Views:
932
Email this article 